Theravance Biopharma logo

Theravance Biopharma share price today

(TBPH)

Theravance Biopharma share price is $9.19 & ₹788.59 as on 7 Jan 2025, 2.30 'hrs' IST

$9.19

-0.12

(-1.29%)

Market is closed - opens 8 PM, 07 Jan 2025

View live Theravance Biopharma share price in Dollar and Rupees. Guide to invest in Theravance Biopharma stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Theravance Biopharma, along with analyst recommendations, forecasts, and comprehensive financials.

Theravance Biopharma share price movements

  • Today's Low: $9.14
    Today's High: $9.44

    Day's Volatility :3.12%

  • 52 Weeks Low: $7.44
    52 Weeks High: $10.87

    52 Weeks Volatility :31.55%

Theravance Biopharma Returns

PeriodTheravance Biopharma IncSector (Health Care)Index (Russel 2000)
3 Months
17.4%
-8.4%
0.0%
6 Months
4.37%
-3.8%
0.0%
1 Year
-8.73%
-0.1%
0.0%
3 Years
-27.32%
2.9%
-19.8%

Theravance Biopharma Key Statistics

in dollars & INR

Previous Close
$9.31
Open
$9.3
Today's High
$9.435
Today's Low
$9.1408
Market Capitalization
$462.7M
Today's Volume
$127.3K
52 Week High
$10.87
52 Week Low
$7.44
Revenue TTM
$63.2M
EBITDA
$-38.2M
Earnings Per Share (EPS)
$-1.03
Profit Margin
-78.18%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-22.88%

How to invest in Theravance Biopharma from India?

It is very easy for Indian residents to invest directly in Theravance Biopharma from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Theravance Biopharma stock in both Indian Rupees (INR) and US Dollars (USD). Search for Theravance Biopharma or TBPH on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Theravance Biopharma or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Theravance Biopharma shares which would translate to 0.093 fractional shares of Theravance Biopharma as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Theravance Biopharma, in just a few clicks!

Returns in Theravance Biopharma for Indian investors in Rupees

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Theravance Biopharma investment value today

Current value as on today

₹93,321

Returns

₹6,679

(-6.68%)

Returns from Theravance Biopharma Stock

₹9,902 (-9.9%)

Dollar Returns

₹3,223 (+3.22%)

Indian investors sentiment towards Theravance Biopharma

-50%

Period: Oct 8, 2024 to Jan 6, 2025. Change in 30 Days versus previous period

Search volume for Theravance Biopharma on INDmoney from India has reduced in the last 30 days as on Jan 7, 2025. -50% less investors are searching Theravance Biopharma in the last 30 days versus the previous period.

Global Institutional Holdings in Theravance Biopharma

  • Madison Avenue Partners, LP

    19.34%

  • Weiss Asset Management LP

    15.16%

  • Newtyn Management LLC

    9.15%

  • BlackRock Inc

    7.69%

  • Irenic Capital Management LP

    5.61%

  • Vanguard Group Inc

    4.17%

Analyst Recommendation on Theravance Biopharma

Buy

    72%Buy

    27%Hold

    0%Sell

Based on 11 Wall street analysts offering stock ratings for Theravance Biopharma(by analysts ranked 0 to 5 stars)

Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
7
7
Hold
3
3
3
Sell
0
0
0

Analyst Forecast on Theravance Biopharma

What analysts predicted

Upside of 43.63%

Current:

$9.19

Target:

$13.20

Insights on Theravance Biopharma

  • Price Movement

    In the last 7 days, TBPH stock has moved down by -1.7%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, 14.25M → 16.86M (in $), with an average increase of 15.5% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -16.52M → -12.69M (in $), with an average increase of 30.2% per quarter
  • TBPH vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 23.7% return, outperforming this stock by 33.9%
  • TBPH vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 55.2% return, outperforming this stock by 82.0%
  • Price to Sales

    ForTBPH every $1 of sales, investors are willing to pay $7.2, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $14.2 for every $1 of sales.

Theravance Biopharma Financials in INR & Dollars

FY18Y/Y Change
Revenue
$60.4M
↑ 292.37%
Net Income
$-215.5M
↓ 24.48%
Net Profit Margin
-357.01%
↑ 1497.96%
FY19Y/Y Change
Revenue
$73.4M
↑ 21.61%
Net Income
$-236.5M
↑ 9.71%
Net Profit Margin
-322.08%
↑ 34.93%
FY20Y/Y Change
Revenue
$71.9M
↓ 2.12%
Net Income
$-278.0M
↑ 17.58%
Net Profit Margin
-386.9%
↓ 64.82%
FY21Y/Y Change
Revenue
$55.3M
↓ 23.03%
Net Income
$-199.4M
↓ 28.27%
Net Profit Margin
-360.55%
↑ 26.35%
FY22Y/Y Change
Revenue
$51.3M
↓ 7.17%
Net Income
$-92.8M
↓ 53.45%
Net Profit Margin
-180.78%
↑ 179.77%
FY23Y/Y Change
Revenue
$57.4M
↑ 11.84%
Net Income
$-55.2M
↓ 40.54%
Net Profit Margin
-96.11%
↑ 84.67%
Q2 FY23Q/Q Change
Revenue
$13.7M
↑ 31.99%
Net Income
$-15.6M
↓ 29.17%
Net Profit Margin
-113.79%
↑ 98.25%
Q3 FY23Q/Q Change
Revenue
$15.7M
↑ 14.14%
Net Income
$-9.0M
↓ 42.79%
Net Profit Margin
-57.03%
↑ 56.76%
Q4 FY23Q/Q Change
Revenue
$17.6M
↑ 11.93%
Net Income
$-8.5M
↓ 4.91%
Net Profit Margin
-48.45%
↑ 8.58%
Q1 FY24Q/Q Change
Revenue
$14.5M
↓ 17.43%
Net Income
$-11.7M
↑ 37.05%
Net Profit Margin
-80.42%
↓ 31.97%
Q2 FY24Q/Q Change
Revenue
$14.3M
↓ 1.7%
Net Income
$-16.5M
↑ 41.71%
Net Profit Margin
-115.94%
↓ 35.52%
Q3 FY24Q/Q Change
Revenue
$16.9M
↑ 18.32%
Net Income
$-12.7M
↓ 23.18%
Net Profit Margin
-75.28%
↑ 40.66%
FY18Y/Y Change
Profit
$59.7M
↑ 537.61%
FY19Y/Y Change
Profit
$-145.8M
↓ 344.46%
FY20Y/Y Change
Profit
$-189.1M
↑ 29.67%
FY21Y/Y Change
Profit
$48.0M
↓ 125.4%
FY22Y/Y Change
Profit
$44.8M
↓ 6.8%
FY23Y/Y Change
Profit
$16.8M
↓ 62.46%
Q2 FY23Q/Q Change
Profit
$12.4M
↑ 41.66%
Q3 FY23Q/Q Change
Profit
$14.4M
↑ 15.66%
Q4 FY23Q/Q Change
Profit
$13.2M
↓ 7.82%
Q1 FY24Q/Q Change
Profit
$13.0M
↓ 1.98%
Q2 FY24Q/Q Change
Profit
$4.3M
↓ 66.83%
Q3 FY24Q/Q Change
Profit
$16.9M
↑ 292.1%
FY18Y/Y Change
Operating Cash Flow
$-112.9M
↓ 43.86%
Investing Cash Flow
$176.7M
↓ 413.68%
Financing Cash Flow
$225.2M
↑ 13499.03%
FY19Y/Y Change
Operating Cash Flow
$-238.2M
↑ 111.04%
Investing Cash Flow
$-83.1M
↓ 147.0%
Financing Cash Flow
$1.3M
↓ 99.43%
FY20Y/Y Change
Operating Cash Flow
$-250.4M
↑ 5.12%
Investing Cash Flow
$10.7M
↓ 112.91%
Financing Cash Flow
$263.1M
↑ 20278.39%
FY21Y/Y Change
Operating Cash Flow
$-207.9M
↓ 16.99%
Investing Cash Flow
$124.5M
↑ 1061.22%
Financing Cash Flow
$91.9M
↓ 65.08%
FY22Y/Y Change
Operating Cash Flow
$-187.0M
↓ 10.04%
Investing Cash Flow
$1.2B
↑ 826.96%
Financing Cash Flow
$-758.8M
↓ 926.05%
Q2 FY23Q/Q Change
Operating Cash Flow
$-12.4M
↑ 10.83%
Investing Cash Flow
$11.0M
↓ 125.66%
Financing Cash Flow
$-80.7M
↑ 43.46%

Theravance Biopharma Technicals Summary

Sell

Neutral

Buy

Theravance Biopharma is currently in a neutral trading position according to technical analysis indicators.

Theravance Biopharma Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Theravance Biopharma Inc
-6.81%
4.37%
-8.73%
-27.32%
-61.54%
Regeneron Pharmaceuticals, Inc.
-8.86%
-31.87%
-20.46%
15.59%
87.28%
Biontech Se
-4.16%
43.82%
3.49%
-49.66%
167.6%
Alnylam Pharmaceuticals, Inc.
-8.45%
-8.03%
19.03%
56.02%
98.44%
Vertex Pharmaceuticals Incorporated
-14.11%
-16.23%
-2.87%
81.78%
76.8%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Theravance Biopharma Inc
NA
NA
-0.05
-0.11
-0.23
-0.06
NA
3.79
Regeneron Pharmaceuticals, Inc.
17.61
17.61
1.06
45.07
0.17
0.07
NA
272.04
Biontech Se
160.8
NA
0.04
-3.11
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
32.84
NA
1.06
0.51
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Theravance Biopharma Inc
Buy
$462.7M
-61.54%
NA
-78.18%
Regeneron Pharmaceuticals, Inc.
Buy
$78.3B
87.28%
17.61
33.61%
Biontech Se
Buy
$27.3B
167.6%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Buy
$30.4B
98.44%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Buy
$103.7B
76.8%
32.84
-4.51%

About Theravance Biopharma

theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
Organization
Theravance Biopharma
Employees
99
CEO
Mr. Rick E. Winningham M.B.A.
Industry
Health Technology

Management People of Theravance Biopharma

NameTitle
Mr. Rick E. Winningham M.B.A.
CEO & Director
Mr. Aziz Sawaf C.F.A.
Senior VP & CFO
Mr. Stuart Knight
Senior VP of IT&I and Chief Information Officer
Ms. Gail B. Cohen
Vice President of Corporate Communications & Investor Relations
Mr. Brett A. Grimaud Esq.
Senior VP, General Counsel & Secretary
Ms. Rhonda F. Farnum
Chief Business Officer and Senior VP of Commercial & Medical Affairs
Ms. Stacy L. Pryce
Senior VP & Chief Strategy Officer
Dr. Aine Miller Ph.D.
Senior VP of Development & Head of Ireland Office

Important FAQs about investing in Theravance Biopharma from India :

What is Theravance Biopharma share price today?

Theravance Biopharma share price today stands at $9.19, Open: $9.30 ; Previous Close: $9.31 ; High: $9.44 ; Low: $9.14 ; 52 Week High: $10.87 ; 52 Week Low: $7.44. The stock opens at $9.30, after a previous close of $9.31. The stock reached a daily high of $9.44 and a low of $9.14, with a 52-week high of $10.87 and a 52-week low of $7.44.

Can Indians buy Theravance Biopharma shares?

Yes, Indians can invest in the Theravance Biopharma (TBPH) from India.

With INDmoney, you can buy Theravance Biopharma at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Theravance Biopharma at zero transaction cost.

How can I buy Theravance Biopharma shares from India?

It is very easy to buy Theravance Biopharma from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Theravance Biopharma be purchased?

Yes, you can buy fractional shares of Theravance Biopharma with INDmoney app.

What are the documents required to start investing in Theravance Biopharma stocks?

To start investing in Theravance Biopharma, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Theravance Biopharma

Today’s highest price of Theravance Biopharma (TBPH) is $9.44.

Today’s lowest price of Theravance Biopharma (TBPH) is $9.14.

What is today's market capitalisation of Theravance Biopharma

Today's market capitalisation of Theravance Biopharma TBPH is 462.7M

What is the 52 Week High and Low Range of Theravance Biopharma

  • 52 Week High

    $10.87

  • 52 Week Low

    $7.44

What are the historical returns of Theravance Biopharma?

  • 1 Month Returns

    -6.81%

  • 3 Months Returns

    4.37%

  • 1 Year Returns

    -8.73%

  • 5 Years Returns

    -61.54%

Who is the Chief Executive Officer (CEO) of Theravance Biopharma

Mr. Rick E. Winningham M.B.A. is the current Chief Executive Officer (CEO) of Theravance Biopharma.